"Quinazolinones" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Chemicals with two conjoined aromatic rings incorporating two nitrogen atoms and one of the carbons oxidized with a keto oxygen.
| Descriptor ID |
D052999
|
| MeSH Number(s) |
D03.633.100.786.830
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Quinazolinones".
Below are MeSH descriptors whose meaning is more specific than "Quinazolinones".
This graph shows the total number of publications written about "Quinazolinones" by people in this website by year, and whether "Quinazolinones" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2004 | 0 | 1 | 1 |
| 2011 | 0 | 1 | 1 |
| 2012 | 0 | 1 | 1 |
| 2013 | 1 | 1 | 2 |
| 2015 | 2 | 0 | 2 |
| 2017 | 1 | 0 | 1 |
| 2021 | 1 | 0 | 1 |
| 2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Quinazolinones" by people in Profiles.
-
Idelalisib activates AKT via increased recruitment of PI3Kd/PI3Kß to BCR signalosome while reducing PDK1 in post-therapy CLL cells. Leukemia. 2022 07; 36(7):1806-1817.
-
Pilot Study of Dacomitinib for Patients With Metastatic EGFR-Mutant Lung Cancers With Disease Progression After Initial Treatment With Osimertinib. JCO Precis Oncol. 2021; 5.
-
Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials. Lancet Haematol. 2017 Apr; 4(4):e176-e182.
-
Dose-dependent suppression of human photoparoxysmal response with the competitive AMPA/kainate receptor antagonist BGG492: Clear PK/PD relationship. Epilepsia. 2015 Jun; 56(6):924-32.
-
Inhibition of the mitochondrial fission protein dynamin-related protein 1 improves survival in a murine cardiac arrest model. Crit Care Med. 2015 Feb; 43(2):e38-47.
-
Dynamin-related protein 1 (Drp1)-mediated diastolic dysfunction in myocardial ischemia-reperfusion injury: therapeutic benefits of Drp1 inhibition to reduce mitochondrial fission. FASEB J. 2014 Jan; 28(1):316-26.
-
To target or not to target, that is the question. J Clin Oncol. 2013 Mar 20; 31(9):1254.
-
Dynamin-related protein 1-mediated mitochondrial mitotic fission permits hyperproliferation of vascular smooth muscle cells and offers a novel therapeutic target in pulmonary hypertension. Circ Res. 2012 May 25; 110(11):1484-97.
-
Small-molecule inhibitors of the AAA+ ATPase motor cytoplasmic dynein. Nature. 2012 Mar 18; 484(7392):125-9.
-
Apolipoprotein A-I therapy promise, challenges, and disappointment. J Am Coll Cardiol. 2011 Mar 01; 57(9):1120-1.